An interventional study of Blancy Pro in Safety, sponsored by Brainfarma Industria Química e Farmacêutica S/A. Completed at 1 site in Brazil. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-16.
Sponsored by Brainfarma Industria Química e Farmacêutica S/A (part of Hypera Pharma) · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This clinical study will evaluate the dermatological safety and allergenic potential of a cosmetic product. The study will use the Human Repeat Insult Patch Test (HRIPT) and phototest procedures to assess whether the product may cause skin irritation, allergic reactions, photoirritation, or photosensitization after repeated use and exposure to ultraviolet light.
Participants will receive applications of the investigational product under controlled conditions and will undergo dermatological evaluations throughout the study. The results will help determine the product's skin compatibility and safety for consumer use.
This is a single-center, single-blind, non-comparative clinical study designed to evaluate the dermal compatibility and allergenic potential of an investigational cosmetic product using the Human Repeat Insult Patch Test (HRIPT) and phototest procedures.
The HRIPT phase will assess primary dermal irritation, cumulative irritation, and skin sensitization potential through repeated applications of patches containing the investigational product to the participants' backs under maximized conditions. The practical phase lasts six weeks and includes three weeks of product application, two weeks of rest, and one challenge week with product reapplication on a previously untreated skin site.
The phototest phase will assess the photoirritant and photosensitizing potential of the investigational product following controlled exposure to ultraviolet radiation. Product-containing patches will be applied to the skin and, after removal, the test sites will undergo controlled ultraviolet irradiation. The practical phase lasts five weeks and includes induction, rest, and challenge phases.
Dermatological evaluations will be performed according to standardized criteria, including assessments based on the International Contact Dermatitis Research Group (ICDRG) scale, to confirm the absence of clinically significant irritant, allergenic, photoirritant, or photosensitizing reactions.
Brainfarma Industria Química e Farmacêutica S/A is the lead sponsor of 15 studies on the registry; 7 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For the phototest procedure, only participants with Fitzpatrick skin phototypes II and III will be eligible.
Exclusion Criteria:
Additional Exclusion Criteria for the Phototest:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will undergo Human Repeat Insult Patch Test (HRIPT) and phototest procedures using the investigational cosmetic product to evaluate dermatological safety, skin irritation, skin sensitization, photoirritation, and photosensitization potential.
Other: Blancy Pro
Blancy Pro is a cosmetic product evaluated for dermatological safety, skin sensitization, photoirritation, and photosensitization potential. Participants will undergo Human Repeat Insult Patch Test (HRIPT) and phototest procedures involving repeated applications of the product under controlled conditions, followed by dermatological assessments to evaluate skin compatibility and the absence of allergenic reactions.
Dermal Irritation Assessed by Human Repeat Insult Patch Test (HRIPT) Using ICDRG Criteria
Dermal irritation following application of Blancy Pro will be assessed using the Human Repeat Insult Patch Test (HRIPT). Patches containing the investigational product and control patches (saline solution, mineral oil, patch without product, and adhesive tape control) will be applied to the lateral back. Skin reactions will be evaluated 48 hours (Day 3) and 96 hours (Day 5) after application according to the International Contact Dermatitis Research Group (ICDRG) grading scale. Skin reactions will be graded according to the International Contact Dermatitis Research Group (ICDRG) criteria, ranging from 0 (negative reaction) to 4 (strong positive reaction). Higher grades indicate greater skin reactivity.
Time frame: Day 3 and Day 5
Cumulative Dermal Irritation Assessed by Human Repeat Insult Patch Test (HRIPT) Using ICDRG Criteria
Cumulative dermal irritation following repeated applications of Blancy Pro will be assessed using the Human Repeat Insult Patch Test (HRIPT). Patches containing the investigational product and control materials will be repeatedly applied to the lateral back over a 3-week induction period. Skin reactions will be evaluated 15 to 30 minutes after patch removal and graded according to the International Contact Dermatitis Research Group (ICDRG) criteria. Skin reactions will be graded according to the International Contact Dermatitis Research Group (ICDRG) criteria, ranging from 0 (negative reaction) to 4 (strong positive reaction). Higher grades indicate greater skin reactivity.
Time frame: Day 3, Day 5, Day 8, Day 10, Day 12, Day 15, Day 17, and Day 19
Dermal Sensitization Assessed by Human Repeat Insult Patch Test (HRIPT) Challenge Phase Using ICDRG Criteria
Dermal sensitization following repeated application of Blancy Pro will be assessed during the Human Repeat Insult Patch Test (HRIPT) challenge phase. After a two-week rest period, patches containing the investigational product and control materials will be applied to previously unexposed skin sites. Skin reactions will be evaluated 15 to 30 minutes after patch removal and graded according to the International Contact Dermatitis Research Group (ICDRG) criteria. Skin reactions will be graded according to the International Contact Dermatitis Research Group (ICDRG) criteria, ranging from 0 (negative reaction) to 4 (strong positive reaction). Higher grades indicate greater skin reactivity.
Time frame: Day 38 and Day 39
Dermal Photoirritation Assessed by Phototest Using ICDRG Criteria
Dermal photoirritation following application of Blancy Pro will be assessed using phototest procedures. Patches containing the investigational product and control materials (saline solution, mineral oil, patch without product, and adhesive tape control) will be applied to the medial back. After 24 hours, patches will be removed, skin reactions will be assessed, and the test sites will be exposed to ultraviolet A (UVA) radiation at a dose of 5 J/cm². Additional assessments will be performed 48 hours after irradiation according to the International Contact Dermatitis Research Group (ICDRG) grading criteria. Skin reactions will be graded according to the International Contact Dermatitis Research Group (ICDRG) criteria, ranging from 0 (negative reaction) to 4 (strong positive reaction). Higher grades indicate greater skin reactivity.
Time frame: Day 2 and Day 4
Dermal Photosensitization Assessed by Phototest Induction Phase Using ICDRG Criteria
Dermal photosensitization following repeated application of Blancy Pro and controlled ultraviolet A (UVA) exposure will be assessed during the phototest induction phase. Patches containing the investigational product and control materials will be applied to the medial back and irradiated with UVA at a dose of 5 J/cm². Skin reactions will be evaluated 15 to 30 minutes after patch removal and graded according to the International Contact Dermatitis Research Group (ICDRG) criteria. Skin reactions will be graded according to the International Contact Dermatitis Research Group (ICDRG) criteria, ranging from 0 (negative reaction) to 4 (strong positive reaction). Higher grades indicate greater skin reactivity.
Time frame: Day 2, Day 4, Day 5, Day 8, Day 10, and Day 12
Dermal Photosensitization Assessed by Phototest Challenge Phase Using ICDRG Criteria
Dermal photosensitization following repeated application of Blancy Pro will be assessed during the phototest challenge phase. After a two-week rest period, patches containing the investigational product and control materials will be applied to two previously unexposed skin sites. One test area will be irradiated with ultraviolet A (UVA) radiation at a dose of 5 J/cm². Skin reactions in both test areas will be evaluated 15 to 30 minutes after patch removal and graded according to the International Contact Dermatitis Research Group (ICDRG) criteria. Skin reactions will be graded according to the International Contact Dermatitis Research Group (ICDRG) criteria, ranging from 0 (negative reaction) to 4 (strong positive reaction). Higher grades indicate greater skin reactivity.
Time frame: Day 30 and Day 32
Plan to share: No
No publications or documents are linked to this record.
Ran from Jul 2026 to primary completion in Aug 2026, 1 month.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Brainfarma Industria Química e Farmacêutica S/A →